Allogene Therapeutics Inc - ESG Rating & Company Profile powered by AI
This analysis of Allogene Therapeutics Inc is prepared by All Street Sevva using proprietary machine learning. Complete ESG assessment of Allogene Therapeutics Inc can be accessed by signing up for free. Check the end of the webpage for potential risks for Allogene Therapeutics Inc based on sector, geography and marketcap.
Allogene Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 5.3, social score of 2.3 and governance score of 4.0.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
| 1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
| ... | ... | ... | |
| 1089 | Allogene Therapeutics Inc | 3.9 | Medium |
| 1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
| 1089 | Hua Medicine | 3.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Allogene Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Allogene Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Allogene Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Allogene Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Allogene Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Allogene Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Allogene Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Allogene Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Allogene Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Allogene Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Allogene Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Allogene Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Allogene Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Allogene Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Allogene Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Allogene Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Allogene Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Allogene Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.